NCT00982657 - A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Solid Tumor

Interventions

DRUG

CVX-060 + sunitinib

CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

DRUG

CVX-060 + sunitinib

CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

DRUG

CVX-060 + sunitinib

CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

DRUG

CVX-060 + sunitinib

CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

DRUG

CVX-060 + sunitinib

CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)

DRUG

Sunitinib

50 mg sunitinib daily (4 out of 6 weeks)

Trial Locations (7)

Boston Baskin Cancer Foundation, Memphis

Boston Baskin Cancer Foundation, Bartlett

Boston Baskin Cancer Foundation, Germantown

Boston Baskin Cancer Foundation, Southaven

Premiere Oncology of Arizona, Scottsdale

Premiere Oncology, A Medical Corporation, Santa Monica

Providence Portland Medical Center, Portland